This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $450,764 to Tufts University School of Medicine to conduct research on understanding the heterogeneity of necroptotic cell death and mechanisms of necroptosis escape. The research aims to validate and optimize a single-cell assay to measure cell death status and inflammatory gene expression changes in cells...
The National Institute of General Medical Sciences (NIGMS) awarded a $397,771 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to The Research Foundation For The State University Of New York (RF SUNY) to study the role of lipids in regulating necroptosis, a form of regulated cell death. The project aims to identify lipid modulators of necroptosis, investigate mechanisms that activate lipid production during necroptosis, and characterize how lipid...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), is providing $344,111 to Loyola University of Chicago to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The primary objectives are to investigate whether inhibition of RIPK1 and TBK1 can prevent MDS and eliminate mutant hematopoietic stem/progenitor cells, thereby restoring blood cell counts and preventing...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $595,047.00 to the University of California, Los Angeles (UCLA) to investigate non-apoptotic forms of cell death in glioblastoma (GBM), the most deadly primary brain tumor in adults. The key objectives are to: 1) Define the mechanistic basis for GBM sensitivity to a novel form of...
The National Cancer Institute (NCI) awarded a $2,489,032 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The 5-year award, effective August 1, 2025, will support three highly integrated research projects focused on determining the roles, regulation, and underlying mechanisms of lipid metabolism in ferroptosis, a form of iron-dependent cell death, and exploring novel cancer therapeutic approaches based on these...
This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $161,400 to Mayo Clinic to conduct research on "Targeting Ferroptosis in Cholangiocarcinoma with siRNA-based Nanovesicles". The project aims to elucidate the therapeutic benefits of ferroptosis, an iron-dependent cell death pathway, in both sensitive and resistant cholangiocarcinoma (CCA) cells, a highly lethal liver and biliary tract cancer....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $350,000 in funding to the University of Washington to support research on the transcriptional outputs of the necroptotic cell death pathway. The research aims to define the specific interactions and transcriptional programs activated by necroptosis pathway components, study the role of necroptosis activation in...
This $393,750.00 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will fund a 5-year research project to explore the fundamental cellular mechanisms driving cellular senescence in macrophages. The key objectives of this research project are to gain a deeper understanding of the cellular and molecular mechanisms underlying senescent macrophage biology. This includes investigating the roles...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
SYSTEMS AND NETWORK-LEVEL REGULATION OF CELL DEATH - PROJECT SUMMARY/ABSTRACT OUR LAB STUDIES MECHANISMS THAT CONTROL REGULATED CELL DEATH (RCD). RECENT STUDIES HAVE UNCOVERED THE EXISTENCE OF 15 DISTINCT FORMS OF RCD. THESE INCLUDE DIFFERENT FORMS OF APOPTOSIS, AND TWELVE MECHANISTICALLY DISTINCT FORMS OF REGULATED NECROSIS, INCLUDING FERROPTOSIS, NECROPTOSIS, OXEIPTOSIS, AND PARTHANATOS. IN GENERAL, RCD DESCRIBES SITUATIONS IN WHICH CELL DEATH RESULTS FROM THE USE OF SPECIFIC MECHANISMS TO SENSE STRESS, DEFINED SIGNALING CASCADES TO TRANSMIT INFORMATION, AND USE OF SPECIFIC EFFECTOR MOLECULES THAT DISMANTLE OR RUPTURE THE CELL. THUS, A KEY FEATURE OF ALL FORMS OF RCD IS THAT DEATH IS NOT AN INEVITABLE CONSEQUENCE OF OVERWHELMING STRESS, BUT RATHER, A DECISION WHICH IS PROACTIVELY MADE BY THE CELL. FOR MOST FORMS OF RCD, HOW THESE DECISIONS ARE MADE REMAINS UNCLEAR. OVER THE PAST FIVE YEARS, WE HAVE FOCUSED ON UNDERSTANDING HOW DIFFERENT FORMS OF DEATH ARE REGULATED AND IDENTIFYING FEATURES THAT CONTRIBUTE TO VARIATION IN CELL DEATH RESPONSES. OUR WORK HAS REVEALED THAT VARIATION IN CELL DEATH OUTCOMES IS OFTEN CAUSED BY INHIBITORY INTERACTIONS BETWEEN DIFFERENT CELL DEATH PATHWAYS. WHILE, OUR WORK CLEARLY DEMONSTRATES THAT DEATH PATHWAYS INHIBIT EACH OTHER PHENOTYPICALLY, MECHANISMS OF INTERACTION REMAIN UNCLEAR, LARGELY DUE TO OUR LIMITED UNDERSTANDING OF MOST FORMS OF REGULATED NECROSIS. OVER THE NEXT FIVE YEARS, WE AIM TO UNDERSTAND - WITH MECHANISTIC DETAIL - HOW DIFFERENT TYPES OF DEATH INTERACT, AND THE THERAPEUTIC IMPLICATIONS OF THESE INTERACTIONS. TO FACILITATE THESE EFFORTS, WE HAVE DEVELOPED NEW EXPERIMENTAL AND COMPUTATIONAL APPROACHES FOR STUDYING CELL DEATH, NEW GENETIC SCREENING APPROACHES FOR IDENTIFYING DEATH REGULATORY GENES, AND NEW COMPUTATIONAL TOOLS FOR INFERRING THE ACTIVATION DYNAMICS AND CIRCUITRY OF DEATH REGULATORY PROCESSES. COMBINED, THESE NEW METHODS ALLOW US TO STUDY EVERY CELL DEATH PATHWAY, EACH WITH EQUAL PRECISION AND SENSITIVITY, AND WITH UNPRECEDENTED EASE AND THROUGHPUT. USING THESE METHODS, WE WILL IDENTIFY MECHANISMS OF REGULATION AND MECHANISMS OF COORDINATION BETWEEN APOPTOTIC AND NON-APOPTOTIC FORMS OF DEATH. WE WILL EXPLORE THE IMPLICATIONS OF INTERACTIONS BETWEEN DEATH PATHWAYS ON THE EFFICACY OF COMBINATION DRUG THERAPIES. FINALLY, WE WILL CHARACTERIZE UNEXPECTED DEATH REGULATORY PATHWAYS THAT WE HAVE IDENTIFIED IN THE CONTEXT OF DYSREGULATED GENE EXPRESSION. OUR VISION IS THAT OUR DEEP INSIGHTS INTO THE MECHANISMS OF RCD WILL HAVE IMMEDIATE THERAPEUTIC IMPLICATIONS FOR DISEASES LIKE CANCER, WHERE THERAPIES NEED TO KILL CANCER CELLS WITH SELECTIVITY AND PRECISION. TO FACILITATE THIS VISION, OUR APPROACH IS TO STUDY CELL DEATH IN NORMAL AND CANCER CELLS, IN THE CONTEXT OF DRUG THERAPY. ADDITIONALLY, TO IMPROVE OUR ABILITY TO TRANSLATE OUR FINDINGS TO OTHER RELEVANT CONTEXTS, WE STUDY CELL DEATH ACROSS VARIED ENVIRONMENTAL AND GENETIC CONTEXTS, AND WE USE MATHEMATICAL MODELING AND BIOINFORMATIC ANALYSES TO IDENTIFY FEATURES THAT ARE PREDICTIVE OF THE OBSERVED PHENOTYPES.